Seisuke Nagase

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Takashi Seto, Terufumi Kato, Makoto Nishio et al. · The Lancet Oncology · 2014 · 749 citations

Medicine, Oncology, Pharmacology +14

Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial

Takehito Shukuya, Takeharu Yamanaka, Takashi Seto et al. · The Lancet Oncology · 2015 · 86 citations

Medicine, Oncology, Pharmacology +12

Detection of unsuspected distant metastases and/or regional nodes by FDG-PET in LD-SCLC scan in apparent limited-disease small-cell lung cancer

Seiji Niho, Hirofumi Fujii, Koji Murakami et al. · Lung Cancer · 2007 · 68 citations

Medicine, Nuclear Medicine, Oncology +15

Histology and Smoking Status Predict Survival of Patients with Advanced Non–Small-Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study 3906L

Yoshihito Kogure, Masahiko Ando, Hideo Saka et al. · Journal of Thoracic Oncology · 2013 · 47 citations · Full text

Medicine, Oncology, Neoplasia +7

Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study

Isamu Okamoto, Kazuko Sakai, Satoshi Morita et al. · Oncotarget · 2014 · 32 citations · Full text

Medicine, Molecular Genetics, Oncology +17